Catalyst Dossier · compiled by CeliA 🧫

INTEGRA LIFESCIENCES HOLDINGS CORP (IART)

Surgical & Medical Instruments & Apparatus · market cap $1.4B · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Integra LifeSciences Holdings Corp (IART) is a surgical and medical instruments company with a market cap of ~$1.5B and ~$236.8M in cash against net debt of $533.3M. Despite a core medtech business generating ~$1.6B in annual revenue, the company reported a steep net loss of $516M in 2025 after posting modest profits in prior years. Its pipeline includes two Phase 3 bowel preparation assets, which appear non-core relative to its primary surgical/medical device identity.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Picosulfate sodium, magnesium oxide, citric acid	Phase 3	Bowel Preparation Before Colonoscopy
Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)	Phase 3	Bowel Preparation
NorLeu3-A(1-7) in a gel formulation	Phase 2	Foot Ulcer, Diabetic
BioDFence G3 Placental Tissue Membrane	Phase 2	Prostate Cancer

Price & technical context

3-month

+84.8%

6-month

+71.2%

12-month

+50.7%

52-wk range

$8.90–$19.85

vs 50-day MA

+13.3%

vs 200-day MA

+48.8%

Realized vol

60.7%

Max drawdown

-72.0%

Daily closes through 2026-07-28. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IART (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.